Dispersome® – An Amorphous Mixture

A technology based on a natural, biodegradable excipient

The Dispersome® technology uses high quality whey protein, an environmentally friendly by-product from cheese production, to improve the solubility and bioavailability of poorly soluble drugs.

Zerion Pharma is a Danish pharmaceutical company transforming the pharmaceutical landscape for the formulation of poorly soluble drugs that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, Dispersome®, we aim to develop new treatment options for patients across all small-molecule therapy areas. We are focused on improving the formulation of poorly soluble oral drugs, both for innovator drugs and existing drug products.

Technology that is changing the future

Dispersome® Platform

Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.

Improving Outcomes

By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.

Compatible Technology

Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.

Dispersome® explained in 1 minute:

Poor drug solubility is one of the biggest challenges preventing the development of novel drugs. Up to 90 % of all new drug molecules are poorly soluble, which can be a problem as the drug must dissolve in order to be absorbed and reach its pharmacological target. Many otherwise promising drug candidates are discontinued during early-stage development due to poor bioavailability resulting from poor solubility.

Our Dispersome® platform is based on a novel class of excipients that allows formulating poorly soluble small molecule drugs as stable amorphous dispersions with a high drug load. The amorphous form of a drug can increase its inherent solubility and by increasing solubility and dissolution rate the Dispersome® technology can improve bioavailability of drugs and reduce the dose required. To form a Dispersome® formulation the crystalline drug compound is simply mixed with the WPI and processed into an amorphous mixture.

A unique enabling excipient

The Dispersome® technology stabilizes the amorphous form by forming a unique drug dispersion in a protein-based matrix, resulting in exceptional drug loading and dissolution enhancement. Whey proteins have demonstrated an excellent ability to form amorphous mixtures and are both inexpensive to manufacture and safe to use. Compared with conventional polymeric excipients such as PVP, PVPVA and HPMCAS, WPI allows higher drug loading (>50%) and dissolution rate while maintaining stability.

The Dispersome® technology not only makes it possible to develop drugs that would otherwise never reach the market. In many cases, the technology outperforms other technological solutions on key parameters with major improvements in both drug loading, solubility, and bioavailability. Moreover, by replacing the use of fossil polymers and reducing the amount of drug needed per tablet, it saves resources in the manufacture and reduces toxic drug waste into the aquatic environment.

Interested in more information on the Dispersome technology and Zerion Pharma?

Name *

First

Last

Email *

Company *

Address *

Address Line 1

Address Line 2

City

State / Province / Region

Postal Code

Country

I am interested to get more information on *

Dispersome Technology
Cooperation Request
General information from Zerion Pharma

Comment or Message *

I agree with the privacy policy as per https://www.pharmaexcipients.com/privacy/ . The contact details will be shared with the supplier who holds the request above. The supplier can contact you directly.

Website